U.S. Medical Equipment Stock News

Investors may be wondering if Eli Lilly at around US$1,105 per share is still priced for opportunity or if it already reflects the market's optimism about its future. The stock has returned 3.8% over the past week, 29.8% over the last month, 2.3% year to date, and 50.9% over the past year. This naturally raises questions about how much potential or risk is now reflected in the price. These moves are occurring against a backdrop of ongoing attention on Eli Lilly's drug portfolio and pipeline,...

What Waste Connections stock’s recent slide means for investors Waste Connections (WCN) has drawn attention after its stock declined about 9% over the past month and roughly 13% over the past 3 months, prompting investors to reassess expectations. See our latest analysis for Waste Connections. At a share price of $149.02, Waste Connections is down 14.42% on a year to date share price basis and its 1 year total shareholder return has declined 23.77%, even though the 5 year total shareholder...

Earlier in May 2026, Univar Solutions B.V. expanded its long-standing partnership with Dow to distribute Dow’s silicone additives for plastics and composites across EMEA, while Dow and X-energy received a Finding of No Significant Impact from the U.S. Nuclear Regulatory Commission for their proposed advanced nuclear project in Seadrift, Texas. Together, these moves broaden Dow’s access to specialty materials customers and progress its plans for low-carbon industrial power and steam at a...

Why Crocs (CROX) is on investors’ radar Crocs (CROX) has quietly put together a period of solid share price gains, with the stock up about 7% over the past week, 19% over the past month, and 31% in the past 3 months. See our latest analysis for Crocs. Against this backdrop, Crocs’ recent momentum stands out, with a 30.8% 90 day share price return and a 16.3% 1 year total shareholder return pointing to steadily improving sentiment rather than a short lived spike. If you are comparing Crocs...

The Australian government has filed a lawsuit against 3M (NYSE:MMM) over PFAS "forever chemicals" contamination. The case seeks compensation for environmental and health impacts that authorities link to historical PFAS use. This is one of the first major PFAS actions against 3M outside the US, adding to its global legal exposure. The lawsuit comes at a time when 3M shares trade around $153.13, with the stock up 6.4% over the past month and 5.2% over the past year. Investors now have a fresh...

Why Cohu’s Diamondx Orders Matter for AI Data Center Exposure Cohu (COHU) recently reported multiple orders worth about US$5 million for its Diamondx platform, tied to next generation gallium nitride power devices used in AI data center power architectures. See our latest analysis for Cohu. At a share price of US$52.75, Cohu has seen a sharp 74.67% 90 day share price return and a very strong 209.02% 1 year total shareholder return, which suggests that momentum has been building as investors...

Bandwidth stock reacts to strong recent performance Bandwidth (BAND) has drawn fresh attention after a sharp move in its share price, with the stock up 12.7% over the past day and posting strong gains over the past month and past 3 months. See our latest analysis for Bandwidth. Looking beyond the latest swing, Bandwidth’s recent 30 day share price return of 168.47% and year to date share price return of 356.89% sit alongside a 3 year total shareholder return of 436.94%. This points to...

What ONEOK’s Recent Trading Tells You About the Stock ONEOK (OKE) has seen its stock slide about 6% over the past month, even as its total return over the past 3 years sits well above a multiple of 7x, putting recent moves in context. See our latest analysis for ONEOK. The recent 1-day share price return of down 3.54% and 7-day share price return of down 10.73% contrast with a year-to-date share price return of 12.91% and a 3-year total shareholder return of 66.76%. This suggests that...

Recent performance snapshot With no single headline event driving recent trading, Archer-Daniels-Midland (ADM) has drawn interest as the stock’s recent moves contrast with its longer track record of total returns and its current valuation metrics. See our latest analysis for Archer-Daniels-Midland. ADM’s recent share price move to around US$79.78 comes after a strong run, with a 30 day share price return of 7.42% and a 1 year total shareholder return of 70.48%. This suggests that momentum has...

GDS Holdings (NasdaqGM:GDS) announced that long-serving Chairman Mr. Lim Ah Doo has resigned from the board. Ms. Hua (Kathy) Chen has been appointed as an independent director and Chair of the Audit Committee, taking over key governance responsibilities. The leadership transition marks a change in board and committee oversight after Mr. Lim’s 11-year contribution to the company’s corporate governance. For investors watching NasdaqGM:GDS, this governance update comes with the stock at a...

Ocular Therapeutix (OCUL) has been drawing fresh attention after recent trading moves, with the stock closing at US$9.01 and posting mixed short term returns across the past week, month and past 3 months. See our latest analysis for Ocular Therapeutix. Recent trading puts that US$9.01 share price in context, with short term share price momentum firming over the past week but still weaker year to date, while longer term total shareholder returns over one and three years remain positive. If you...

Citi’s initiation of coverage on NextDecade (NEXT) has put fresh attention on the stock, as investors weigh the firm’s view against approaching milestones at the company’s Rio Grande LNG project in Texas. See our latest analysis for NextDecade. At a share price of US$7.91, NextDecade has seen short term momentum cool with a 7 day share price return that declined 6.5%, but the 90 day share price return of 46.75% and 5 year total shareholder return of 224.18% point to a stock where sentiment...

General Electric (GE) is back in focus after GE Aerospace secured a U.S. Air Force contract to advance its GE426 engine for the Autonomous Collaborative Platform program, while also reporting robust Q1 2026 results and reaffirmed guidance. See our latest analysis for General Electric. The latest U.S. Air Force engine contract and solid Q1 2026 update appear to be feeding into renewed optimism, with General Electric's 7 day share price return of 6.9% and 30 day share price return of 14.2%...

Wondering whether Estée Lauder Companies at around US$88.95 is offering fair value or an opportunity? This article walks through what the current price might be telling you. The stock is up 0.7% over the past week and 17.5% over the past month. However, it remains down 16.7% year to date, with a 34.8% gain over 1 year but declines of 50.0% over 3 years and 68.4% over 5 years. The recent rebound therefore sits against a much weaker longer-term picture. Recent headlines around Estée Lauder...

Centrus Energy (LEU) has drawn fresh investor attention after securing significant federal funding and outlining a substantial expansion of its centrifuge manufacturing plant, reinforcing its role as the only licensed HALEU producer in the Western world. See our latest analysis for Centrus Energy. The federal funding and HALEU expansion news come after a period where the share price has fallen 33% year to date to US$182.47, even as the 1 year total shareholder return is 43.77% and the 5 year...

Wondering if Toast's current share price offers value or just extra risk? This article walks through what the numbers say so you can judge whether the stock fits your approach. Toast shares closed at US$26.03, with the stock up 12.4% over the last 7 days, but down 9.0% over 30 days, 23.5% year to date, and 38.3% over the past year, while still showing a 23.5% gain over 3 years. Recent headlines have focused on Toast as a listed point of sale and payments platform for restaurants,...

If you are wondering whether F5 at around US$383 per share offers fair value or is pricing in too much optimism, you are not alone. The stock is down 2.6% over the last week, but up 16.9% over the past month, 49.4% year to date, 34.4% over the last year, 161.3% over three years and 103.1% over five years, which naturally raises questions about what is now baked into the price. Recent coverage has focused on F5's role in application security and multi cloud networking, as investors weigh how...

Federal Signal (FSS) is back on investor radars after recent share price softness, with the stock down about 12% over the past month and roughly 8% over the past 3 months. See our latest analysis for Federal Signal. At a share price of $106.70, the stock has given up some ground recently, with the 7 day share price return down 5.25% and the 30 day share price return down 12.17%. However, the 1 year total shareholder return of 14% and 5 year total shareholder return of 155.39% still point to a...

Duos Technologies Group (DUOT) has reaffirmed its expectation for 2026 revenue to exceed US$50 million and is preparing to present at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026. See our latest analysis for Duos Technologies Group. The reaffirmed 2026 revenue outlook and upcoming Craig Hallum conference appearance come after a sharp 30 day share price return of 63.64% and a 1 year total shareholder return of 76.47%. This suggests momentum has been building...

Unusual Machines (UMAC) has been drawing attention recently, with investors weighing its position in the commercial drone industry, its current share price of US$31.78, and a market cap of about US$1.41b. See our latest analysis for Unusual Machines. Recent trading has been intense, with a 7.36% 1-day share price return, a 131.30% 30-day share price return and a very large 1-year total shareholder return, suggesting strong momentum and rapidly shifting expectations around growth and risk. If...

Gap (GPS) opened Q1 2027 with revenue of US$3,497 million and basic EPS of US$0.92, set against trailing twelve month revenue of US$15.4 billion and EPS of US$2.59 that were tied to 2.3% yearly revenue growth and 9.5% earnings growth. Over the past year, revenue moved from US$15.1 billion in Q1 2026 to US$15.4 billion in Q1 2027 while EPS shifted from US$2.34 to US$2.59, giving investors a clear view of steady top line and earnings expansion. With net profit margins improving from 5.8% to...

Teladoc Health (TDOC) is back in focus after two key developments: a new partnership that puts its virtual care services on Walmart’s Better Care Services platform and an earnings update that drew a sharp stock reaction. See our latest analysis for Teladoc Health. The recent Walmart partnership and earnings update come on top of a sharp 44.68% 90 day share price return and 27.90% 30 day share price return. However, the 3 year total shareholder return is still down 68.91%, so recent momentum...

The U.S. Food and Drug Administration has granted accelerated approval for Hepcludex, the first approved treatment for chronic hepatitis delta virus infection in U.S. adults, which is putting Gilead Sciences (GILD) in focus for many healthcare investors. See our latest analysis for Gilead Sciences. Alongside the Hepcludex approval and updates around Livdelzi and Trodelvy, Gilead’s share price has risen 10.55% year to date and its 1 year total shareholder return is 25.37%, which points to firm...

Earlier this month, Becton, Dickinson and Company introduced the Elyra and Elyra Plus Thulium Fiber Laser Systems in the US, expanding its kidney stone and soft tissue urologic care portfolio with an air-cooled, small-footprint platform aimed at improving procedural efficiency and workflow. The launch underscores BD’s push toward an end-to-end urologic stone management offering, integrating access, visualization, fragmentation, removal, and drainage into a single, cohesive ecosystem for...